New Product Review (September 2003) Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra®)

2004 Journal of family planning and reproductive health care  
Inevitably there are limited long-term safety data for any new contraceptive method, in particular regarding venous thromboembolism and breast or cervical cancer risk. Detailed scientific studies, performed in a small number of women, provide evidence on mode of action. Larger clinical trials examine efficacy, side effects and acceptability. The number of woman-years of exposure is less than for established methods and all available evidence should be considered before prescribing new products.
more » ... However, many existing products have been licensed for many years and may not have been the subject of recent evidence-based assessments. What is the transdermal contraceptive system? Each 20 cm 2 patch delivers 150 mg (micrograms) of norelgestromin (17-deacetyl norgestimate) and 20 mg ethinyl oestradiol (EE) daily into the systemic circulation. 1 Constant serum levels of EE and norelgestromin were observed in an open-label, randomised study over three cycles. 2 Norelgestromin is the primary active metabolite of norgestimate, 1 which itself has been administered orally with EE providing safe effective contraception. 3 group.bmj.com on July 22, 2018 -Published by
doi:10.1783/147118904322701974 pmid:15006313 fatcat:aurdukmn4rd53dbqkbsm4iiizq